

News Release

Suven grants an exclusive license & right to distribute its Malathion Lotion in USA, CANADA and MEXICO to Taro Pharmaceuticals

HYDERABAD, INDIA (March 4, 2014) – SUVEN Life Sciences Limited, a bio-pharmaceutical and contract research and manufacturing company, today announced that it has granted an exclusive license and right to distribute and market its Malathion Lotion USP 0.5% w/v with US Patent # 8,138,366 and ANDA 091559 in USA, Canada and Mexico to Taro Pharmaceuticals North America, Inc., a subsidiary of Taro Pharmaceutical Industries Ltd. (NYSE: TARO). Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair. In consideration for the exclusive license and right to distribute and market Malathion Lotion 0.5%w/v USP in North America, Taro will pay Suven a royalty and the arrangement is effective until April 2028 unless otherwise terminated.

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/ services offerings less competitive;